Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076. [More]
A personalized approach for patients with ccRCC-related mutations

A personalized approach for patients with ccRCC-related mutations

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. [More]
TAZ represents a novel therapeutic target in NSCLC

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report. [More]
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations. [More]
Tamoxifen gel stops breast cancer growth without causing dangerous side effects

Tamoxifen gel stops breast cancer growth without causing dangerous side effects

A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it, according to new Northwestern Medicine- research. [More]
Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. [More]
New knowledge may expand treatments for patients with lung cancer

New knowledge may expand treatments for patients with lung cancer

Studying the most common type of lung cancer, researchers have uncovered mutations in a cell-signaling pathway that plays a role in forming tumors. [More]
TCGA finds novel mutations in key cancer-causing pathway in lung adenocarcinoma

TCGA finds novel mutations in key cancer-causing pathway in lung adenocarcinoma

Researchers from The Cancer Genome Atlas Research Network have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. [More]
CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC). [More]
Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). [More]
Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

Mayo Clinic researchers uncover 31 genes key to clear cell renal cell carcinoma

A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. [More]

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. [More]
Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option

Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population. [More]
Partial nephrectomy predicts survival among metastatic RCC patients

Partial nephrectomy predicts survival among metastatic RCC patients

Cytoreductive nephrectomy predicts improved survival among patients with metastatic renal cell carcinoma and synchronous metastases who have received first-line treatment with sunitinib, indicate study findings. [More]
Genetic variants alter chance of sunitinib dose reduction

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma. [More]

18F-FGD-PET measures predict mRCC TKI response

Positron emission tomography could be used to predict the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy within a couple of weeks of a patient beginning treatment, research suggests. [More]
Single gene defines difference between aggressive and non-aggressive forms of thymoma

Single gene defines difference between aggressive and non-aggressive forms of thymoma

For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy. [More]
Gene in brain promotes kidney cancer, report researchers

Gene in brain promotes kidney cancer, report researchers

A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. [More]
Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years. [More]
Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. [More]